Q1 2027 Laurus Labs Ltd Earnings Call Transcript
Key Points
- Laurus Labs Ltd (BOM:540222) reported a 29% growth in revenue, reaching INR2,026 crores, driven by strong performance in the CDMO segment and affordable medicine portfolio.
- The company achieved a significant expansion in EBITDA margins, which increased by 7 percentage points to 31.8%, reflecting improved operational efficiency.
- The CDMO business saw a remarkable 69% growth, with sales reaching INR835 crores, driven by late-stage clinical and commercial deliveries.
- Laurus Labs Ltd (BOM:540222) maintained healthy gross margins at 62.7%, supported by a favorable product mix and process improvements.
- The company successfully passed 24 quality audits without any critical findings, demonstrating strong compliance and quality assurance.
- The company has increased its CapEx guidance from INR1,000 crores to INR2,000 crores for FY27, indicating higher capital expenditure requirements.
- Despite strong growth, the company did not disclose operating cash flow figures for the quarter, leaving some financial details unclear.
- The constant currency growth was reported at only 2%, which is relatively low compared to the overall revenue growth.
- The company faces potential margin pressures due to global conflicts and raw material cost fluctuations.
- Laurus Bio division, while growing, remains a small contributor to overall revenue, indicating a need for further development and scaling.
Ladies and gentlemen, good day, and welcome to the Laurus Labs Q1 FY27 Earnings Conference Call. (Operator Instructions)
Please note that this conference is being recorded. I now hand the conference over to Mr. Nitin Agarwal. Thank you, and over to you, sir.
Thank you, Bharat. Good evening, everyone, and a very warm welcome to Laurus Labs Q1 F '27 Earnings Call hosted by DAM Capital Advisors Limited.
On the call today, we have representing Laurus Labs management: Dr. Satyanarayana Chava, Founder and CEO; Mr. V. V. Ravi Kumar, Executive Director and CFO; Mr. Krishna Chaitanya Chava, ED, Head CDMO; Mrs. Soumya Chava, ED, Generics and Commercial; and Mr. Vivek Kumar, AVP, Investor Relations.
Before we proceed, I would like you to remind you that some of the statements made during the call today could be forward-looking in nature, and a safe harbor statement to this effect has been included in the press release that has been shared on the company's website. I hand over the call to Dr.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
